Peptide ss 31(tseem hu ua Elamipretide, thawj tus lej npe MTP-131/Bendavia) yog ib qho ntawm cov neeg sawv cev tshaj plaws ntawm cov neeg sib tw molecules hauv chav kawm ntawm "mitochondrial-targeting tetrapeptides," evolved los ntawm aromatic -cationic peptide (SS peptide) tsev neeg tawm tswv yim{6} pab neeg. Nrog cardiolipin (CL) raws li nws lub hom phiaj tseem ceeb, nws txhim kho lub zog metabolism thiab oxidative kev nyuaj siab los ntawm kev kho lub mitochondrial puab membrane microenvironment thiab electron thauj saw (ETC) lub koom haum. Nws tau raug tshawb fawb ntau hauv cov qauv ntawm ntau-system ischemia-reperfusion, mitochondrial kab mob, thiab cov kab mob uas muaj hnub nyoog ntsig txog degenerative, nrog rau hauv kev sim tshuaj thaum ntxov.
Shaanxi Medibridge Biotech Co., Ltd. yog koj qhov kev ntseeg siab peptide tus khub rau kev kawm thiab kev tshawb fawb labs thoob ntiaj teb. Peb muab cov ntaub ntawv tshawb fawb-siv-tsuas yog peptide raw cov ntaub ntawv nrog kev tswj xyuas zoo, kev txhawb nqa teb, thiab lub sijhawm ua haujlwm tau zoo. Peb cov Elamipretide (SS-31/MTP-131, Bendavia) muaj nyob rau ntawm Greater dua los yog sib npaug rau 99.78% purity, nrog rau cov ntaub ntawv meej thiab hloov pauv qhov ntau thiab tsawg kom haum rau koj cov kev xav tau kev kawm.

COA
|
|
||
|
Khoom npe |
CAS Nr |
Batch Number |
|
SIB 31 |
736992-21-5 |
MB2510081437 |
|
Hnub tim tsim khoom |
Hnub Soj Ntsuam |
Hnub Kawg |
|
2025-10-08 |
2025-10-09 |
2027-10-07 |
|
Qauv Qty Base |
Ntim |
Txoj Kev Xeem |
|
5.85 KWG |
10 Gs/BOTTLE |
HPLC |
|
Yam khoom |
Txuj |
Cov txiaj ntsig |
|
Purity |
Ntau dua lossis sib npaug li 98% |
99.78% |
|
Peptide Assay |
Ntau dua lossis sib npaug li 80% |
92.05% |
|
Loj Spectrum |
639.79 |
639.79 |
|
Solubility |
Soluble hauv dej |
Ua raws |
|
Clarity thiab xim ntawm kev daws |
Ntshiab thiab tsis muaj xim |
Ua raws |
|
Sodium ntsev |
<5.0% |
1.15% |
|
Dej |
Tsawg dua lossis sib npaug li 7.0% |
3.51% |
|
Residual Solvent: |
||
|
Methanol |
Tsawg dua lossis sib npaug li 0.3% |
Ua raws |
|
Isopropanol |
Tsawg dua los yog sib npaug li 0.5% |
0.158% |
|
Cov tshuaj acetonitrile |
Tsawg dua lossis sib npaug li 0.041% |
0.019% |
|
Methylene Chloride |
Tsawg dua lossis sib npaug li 0.06% |
0.028% |
|
N,N{0}}Dimethylformamide |
Tsawg dua lossis sib npaug li 0.088% |
Ua raws |
|
Triethylamine |
Tsawg dua lossis sib npaug li 0.032% |
Ua raws |
|
Tert -butyl methyl ether |
Tsawg dua los yog sib npaug li 0.5% |
0.152% |
|
Endotoxin |
Tsawg dua lossis sib npaug li 0.5 EU / mg |
Ua raws |
|
Microbial txwv |
Tag nrho cov kab mob aerobic<100 CFU/g Tag nrho cov poov xab & pwm<50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Cia |
Khaws rau hauv qhov chaw tsaus thiab txias qhuav (-20 txog 8 degree) |
|
|
Xaus |
Cov batch ua raws li IN-HOUSE tus qauv |
|
|
|
||
Specification (rau kev tshawb fawb siv nkaus xwb)
Peb qhov zoo
1. Boosts ETC coupling thiab ATP tso zis; txo ROS ntawm qhov chaw.
2. Ceev ceev, vector-free cell uptake; muaj zog mitochondrial enrichment hauv vitro / hauv vivo.
3. Ntau dua lossis sib npaug li 99% purity (HPLC/MS), tsis tshua muaj endotoxin; Cov ntaub ntawv tshwj xeeb COA thiab MS.
4. Dej-soluble, lyophilized; ruaj khov ntawm -20 degree; yooj yim, reproducible reconstitution.
5. RUO nkaus xwb; ntau pob qhov ntau thiab tsawg; zoo ib yam ntau nrog teb technical support.
|
Daim ntawv |
Qauv Order |
Specification |
|
Cov hmoov nyoos |
1 g |
Purity yog NLT 99.78% |
|
Vials |
10 vials |
3ml / 5ml / 7ml / 15ml vials thiab lwm yam. |
Mechanism of action (peb-tier moj khaum: membrane lipids, proteins, thiab bioenergetics)
1.Membrane-lipid theem: Los ntawm khi cardiolipin (CL), SS-31 curbs CL oxidation thiab imbalance, khaws cia zoo inner-membrane curvature thiab cristae lub koom haum, thiab yog li tswj cov txheej txheem scaffold ntawm mitochondrial zog tsim.
2.Protein theem: Nws stabilizes cov kev npaj ntawm electron thauj saw (ETC) complexes thiab supercomplexes (respirasomes), txo cov off-txoj kev electron leak; Nws kuj txwv tsis pub hloov pauv peroxidase zoo li ntawm cytochrome c, ua kom nws nyob hauv nws lub luag haujlwm electron-carrier thiab damping lipid-peroxidation cascades.
3.Bioenergetic theem: Nws txo qis proton leak thiab txhim kho coupling efficiency, tsa ADP-tsav pa ua pa thiab ATP tiam; nws txo qis ROS ntau lawm ntawm qhov chaw es tsis yog tsuas yog tshem tawm cov radicals; thiab nws txo qhov propensity rau qhib ntawm mitochondrial permeability hloov pore (mPTP), yog li txwv mitochondria-mediated apoptotic cascades.

Muaj peev xwm thiab tshawb xyuas daim ntawv thov (Kev Tshawb Fawb Txog Kev Tshawb Fawb)
1.Mitochondria-hais txog kev mob: Thawj mitochondrial myopathies thiab Barth syndrome (kev kho mob cardiolipin tsis zoo) - ib qho etiology-directed arena qhov twg mechanism thiab kab mob biology sib raug zoo.
2.Cardiovascular–renal: Ischemia–reperfusion raug mob, lub plawv tsis ua hauj lwm, perioperative organ tiv thaiv, thiab mob raum raug mob - nrog rau qhov tseem ceeb ntawm kev nyuaj siab resilience thiab preservation ntawm lub cev muaj nuj nqi.
3.Ophthalmology thiab neurodegeneration: Dry age-related macular degeneration (AMD), optic neuropathies, thiab exploratory work in Parkinson's and Alzheimer's disease - leveraging bioenergetic support and membrane-lipid homeostasis as entry point.
4.Qhov kev tshawb fawb tag nrho: Cov txiaj ntsig tau pom tseeb tshaj plaws nyob rau hauv cov xwm txheej kev ntxhov siab, cim mitochondrial tsis ua haujlwm, lossis cuam tshuam cardiolipin tshuav nyiaj li cas. Qhov loj ntawm cov nyhuv txawv ntawm qhov taw qhia thiab qhov kawg (cov nplais ua haujlwm, lub peev xwm tawm dag zog, pom kev ua haujlwm, lub cev ntim khoom / cov qauv ntsuas).

Kev sib piv nrog rau lwm cov phiaj xwm mitochondrial
|
Yam |
Peptide ss 31(Elamipretide) |
TPP + Cov neeg nqa khoom (MitoQ, SkQ) |
Metabolic Supplementation (CoQ10, NAD + precursors) |
|
Lub hom phiaj hauv paus |
Cardiolipin khi; microenvironment hloov kho |
Δψm tsav tsub zuj zuj; muab cov tshuaj antioxidants |
Replenishes substrates / cofactors |
|
Mechanistic tsom |
Structure-organization-coupling (cristae, ETC supercomplexes) |
"Kev xa khoom" qauv rau mitochondrial ROS scavenging |
"Supply" qauv rau electron nqa / redox pas dej ua ke |
|
Δψm dependence |
Tsawg |
Siab |
Tsis muaj |
|
ROS zoo |
Lowers ntau lawm ntawm qhov chaw |
Scavenes tom qab tsim |
Indirect redox kev them nyiaj yug |
|
Complementarity |
Synergistic nrog cov tshuaj metabolic |
Txawv paradigm |
Theoretically synergistic nrog SS 31 |
Cov teeb meem tseem ceeb rau Kev Tshawb Fawb thiab Kev Txhais Lus
2.Endpoints thiab ncua sij hawm: Coupling-oriented interventions feem ntau yuav tsum tau ntev kev soj ntsuam thiab endpoints uas muaj kev cuam tshuam physiological load (xws li, ce muaj peev xwm, organ workload, low-luminance visual function).
3.Tissue access thiab dose design: Organ-specific barriers (ntshav-retina, blood-brain) materially shape the exposure-response relationship; txoj kev thiab kev tswj hwm yuav tsum tau kho raws li qhov qhia tau.
4.Mechanistic positioning: Kev txo qis ntawm ROS feem ntau yog los ntawm kev tswj hwm qhov chaw thiab microenvironment remodeling es tsis yog ncaj qha radical scavenging -raws li cov txiaj ntsig loj hauv cov ntaub so ntswg ntxhov siab / hnub nyoog thiab kev hloov pauv tsawg kawg hauv cov ntaub so ntswg noj qab haus huv.

Cov tswv yim tswv yim rau kev sim cov ntawv thov (los ntawm tus kws tshawb fawb qhov kev xav)
1.In vitro: feem ntau ua haujlwm 10 nM-1 μM; ua ntej kev ntxhov siab, ischemia-reperfusion, lossis mitochondrial raug mob qauv los daws qhov sib txawv.
2.In vivo: siv cov tshuaj mob hnyav los ntes cov teebmeem kev tiv thaiv, thiab kev siv tshuaj ntev ntev los taug qab cov qauv me me-ua haujlwm rov qab.
3.Readouts: suav nrog mitochondrial coupling (OCR, RCR), lipid peroxidation markers, cristae ultrastructure, thiab electrophysiology / cov leeg lub zog / kev tawm dag zog lub cev lossis kev ntsuas kev ua haujlwm tshwj xeeb.
4.Controls thiab tej yam kev mob: kub, noj zaub mov, oxygen nro, thiab calcium load muaj zog cuam tshuam mitochondrial metrics -match controls thiab batches rigorously.

FAQ
Q: Peptide SS-31 yog dab tsi?
A: Ib qho mitochondria-targeted tetrapeptide (elamipretide) uas khi cardiolipin, stabilizes cristae / ETC coupling, boosts ATP, thiab qis ROS ntawm qhov chaw.
Q: Leej twg nrhiav tau SS-31?
A: Los ntawm Szeto-Schiller peptide series, tsim los ntawm Hazel H. Szeto thiab Peter W. Schiller.
Puas yog Shaanxi Medibridge cov chaw tsim khoom ntawm SS 31?
A: Yog lawm, peb tsis tsuas yog muab SS31 nrog purity tsis tsawg tshaj li 99.78%, tab sis Shaanxi Medibridge Biotech Co., Ltd. kuj yog tus neeg muag khoom peptide.
Q: Puas tuaj yeem SS-31 thim rov qab kev laus?
A: Tsis yog. Nws tsis yog ib qho kev tiv thaiv kev laus thiab tsis pom zoo rau lub hom phiaj ntawd.
Q: SS-31 ua li cas rau lub raum?
A: Hauv kev tshawb fawb raum I / R thiab AKI, nws txhawb nqa mitochondrial coupling thiab txwv kev raug mob oxidative; Kev siv tshuaj kho mob raum kab mob tseem nyob hauv kev tshuaj xyuas.
Cim npe nrov: Tuam Tshoj peptide ss 31 manufacturers, lwm tus neeg, Hoobkas



